JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 NOT FOR PRODUCT PROMOTIONAL USE 1
Forward-Looking Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This presentation also contains certain non-GAAP financial measures, adjusted to include certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com. NOT FOR PRODUCT PROMOTIONAL USE 2 2
Our Strategic Foundation Best of Best of BIOTECH PHARMA Diversified Specialty BioPharma IN N OVATE IN TEGR ATE IMPR O VE People helping patients in their fight against serious disease NOT FOR PRODUCT PROMOTIONAL USE 3
2015: Beginning A New Chapter Leading in Immuno-Oncology Diversified in-line portfolio 3 Early Trial Stops 7 FDA Approvals 43 Global launches A Strong Foundation for Future Growth NOT FOR PRODUCT PROMOTIONAL USE 4
Strategic Priorities Drive business performance Leadership in Immuno-Oncology Diversify for long-term growth Business Development and Capital Allocation NOT FOR PRODUCT PROMOTIONAL USE 5
2015: Leading in Immuno-Oncology LUNG • Only PD-1 indicated for all 2 nd line NSCLC patients • No testing requirement • Strong access and reimbursement MELANOMA • Broad range of treatment options (Mono and combination therapy, 1 st and 2 nd line, adjuvant) • First I-O combination regimen approved RENAL • First I-O agent in 2 nd line • Meaningful improvement over a standard of care NOT FOR PRODUCT PROMOTIONAL USE 6
2015: Leading in Immuno-Oncology Strong US commercial execution I-O Weekly Sales Trends BMS I-O Portfolio Opdivo Yervoy Keytruda 1/2 1/9 1/16 1/23 1/30 2/6 2/13 2/20 2/27 3/6 3/13 3/20 3/27 4/3 4/10 4/17 4/24 5/1 5/8 5/15 5/22 5/29 6/5 6/12 6/19 6/26 7/3 7/10 7/17 7/24 7/31 8/7 8/14 8/21 8/28 9/4 9/11 9/18 9/25 10/2 10/9 10/16 10/23 10/30 11/6 11/13 11/20 11/27 12/4 12/11 Note: This information is an estimate derived from the use of information under license from the following IMS Health information services: Xponent & DDD weekly dollars, for the period of 1/2/2015 through 12/31/2015. IMS expressly reserves all rights, including rights of copying, distribution and republication. Total IO Market – Weekly IMS DDD + Xponent NOT FOR PRODUCT PROMOTIONAL USE 7
2016: Leading in Immuno-Oncology Potentially Registrational Data Tumor Study Design Hodgkin Lymphoma Monotherapy single arm study in second line CheckMate -205 Head and Neck Monotherapy vs. standard of care in second line CheckMate -141 Non-Hodgkin Monotherapy single-arm study in Lymphoma relapsed/refractory diffuse large CheckMate -139 B-cell lymphoma Bladder Monotherapy single arm study in second line bladder CheckMate -275 Glioblastoma Monotherapy vs. standard of care in recurrent glioblastoma CheckMate -143 1L NSCLC Monotherapy vs. chemo in first-line PD-L1 expressers CheckMate -026 NOT FOR PRODUCT PROMOTIONAL USE 8
2016: Diversifying in Immuno-Oncology Next wave of innovation: addressing unmet need Improve outcomes through combinations Patients who do not respond to Opdivo +/- Yervoy Patients who progress after treatment with Opdivo +/- Yervoy Additional tumors, including where signals are not sufficient NOT FOR PRODUCT PROMOTIONAL USE 9
2016: Diversifying in Immuno-Oncology Next wave of innovation: areas of focus T Cell Trafficking and Infiltration Priming & Activation T Cell Activation 8 Additional Antigen I-O Assets anti-LAG3 Presentation in Clinical Urelumab (anti-CD137) Development Antigen anti-GITR T cell Release anti-OX40 Tumor Microenvironment NK Cell Activation NK cell anti-CSF1R IDO Lirilumab anti-CD73 (anti-KIR) BMS assets beginning clinical studies in 2016 NOT FOR PRODUCT PROMOTIONAL USE 10
Strong performance trends – establishing global leadership U.S. NBRx NOAC Market Share – U.S. NBRx NOAC Market Share – Cardiologists (AFib + VTE-Tx) All Physicians (AFib + VTE-Tx) 80% 80% 70% 70% 60% AF/VTE-Tx Share 60% AF/VTE-Tx Share 50% 50% 40% 40% 30% 30% 20% 20% 10% 10% 0% 0% 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15 10/24/14 11/21/14 12/19/14 1/16/15 2/13/15 3/13/15 4/10/15 5/8/15 6/5/15 7/3/15 7/31/15 8/28/15 9/25/15 Eliquis AF/VTE-Tx Xarelto AF/VTE-TX Savaysa Total Pradaxa Total Note: Eliquis and Xarelto (all form strengths) are factored for AF and VTE-Tx indications. Pradaxa and Savaysa are unfactored and include volume across all approved indications. Source: IMS SDI VECTOR. NBRx (New to Brand Rx) = Naïve + Switch to Rx. NOT FOR PRODUCT PROMOTIONAL USE 11
Pursuing Transformational Medicines Beyond Immuno-Oncology Immunoscience Cardiovascular Novel mechanisms Heart Failure in RA and IBD Thrombosis Lupus Genetically Defined Fibrotic Diseases Diseases Lung Monogenic diseases Sentinel populations Liver (eg, Duchenne Muscular Dystrophy, Kidney Progressive Supranuclear Palsy) NOT FOR PRODUCT PROMOTIONAL USE 12
Capital Allocation: A Balanced Approach Continue to be in a solid financial position: • Strong balance sheet • Business development remains a top priority • Dividend commitment 7 th consecutive annual increase NOT FOR PRODUCT PROMOTIONAL USE 13
Select Recent Partnerships Fibrotic I-O Diseases Immuno- Cardio- science vascular Academic Partnerships NOT FOR PRODUCT PROMOTIONAL USE 14
BMS: Poised for Growth Significant growth opportunity driven by I-O and Eliquis Strategic investments behind growth brands Advancing a diverse and innovative pipeline Balanced approach to capital allocation Focused business development NOT FOR PRODUCT PROMOTIONAL USE 15
JP Morgan Healthcare Conference Giovanni Caforio Chief Executive Officer January 12, 2016 NOT FOR PRODUCT PROMOTIONAL USE 16
Recommend
More recommend
